Home › Triple-Negative Breast Cancer › Georgia › Athens
Triple-Negative Breast Cancer clinical trials in Athens, GA
3 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Athens (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RecruitingPhase 3
- University Cancer & Blood Center, LLC ( Site 0023), Athens
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- University Cancer & Blood Center, LLC., Athens
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
RecruitingPhase 1
- University Cancer & Blood Center, Athens
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in Athens
- Non-Small Cell Lung Cancer17 studies
- Lung Cancer9 studies
- Cancer (all types)6 studies
- Colorectal Cancer5 studies
- Breast Cancer5 studies
- Prostate Cancer4 studies
- Colon Cancer3 studies
- Lung Diseases3 studies
- Melanoma3 studies
- Schizophrenia3 studies
- Psychotic Disorders3 studies
- Metastatic Cancer3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.